Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.64 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30235425 | 1.00 | CYP19A1 (0.64) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL29719016 | 0.90 | MAPT (0.61) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL22983913 | 0.90 | MAPT (0.61) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL12381203 | 0.88 | CYP19A1 (0.68) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL3297532 | 0.85 | CYP19A1 (0.65) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL12952789 | 0.84 | CYP19A1 (0.47) | CYP19A1MAPTMEN1KMT2AHTT | |
| SCHEMBL31442728 | 0.83 | MEN1 (0.61) | CYP19A1CNR2MAPTMEN1KMT2A | |
| SCHEMBL944185 | 0.83 | MEN1 (0.61) | CYP19A1CNR2MAPTMEN1KMT2A | |
| SCHEMBL7825236 | 0.83 | CYP19A1 (0.62) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL20607753 | 0.83 | CYP19A1 (0.62) | CYP19A1CNR2MAPTMEN1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111096967-B | Antifungal agent | F2G有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11065228-B2 | Antifungal agents | F2G LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-11065228-B2 | Antifungal agents | F2G LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-20200179340-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200179340-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2020-06-11 | — | — | US | disclosed |
| CN-111096967-A | Antifungal agent | F2G有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10596150-B2 | Antifungal agents | F2G LIMITED (GB) | 2020-03-24 | — | — | US | disclosed |
| US-10596150-B2 | Antifungal agents | F2G LIMITED (GB) | 2020-03-24 | — | — | US | disclosed |
| US-20190314333-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2019-10-17 | — | — | US | disclosed |
| US-20190314333-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2019-10-17 | — | — | US | disclosed |
| WO-2016079536-A1 | ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-9062066-B2 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-23 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2593461-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PHAROSBIOMED CO., LTD. (KR) | 2013-03-21 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | LCK, SRC, MAP3K1 | CYP19A1 2415/4885CNR2 2278/4885MAPT 1230/4885 |
| US-20200179340-A1 | ANTIFUNGAL AGENTS | DPM1, AADAC, PIK3C3 | CYP19A1 2141/4885CNR2 1354/4885MAPT 3096/4885 |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP19A1 2385/4885CNR2 3497/4885MAPT 14/4885 |
| US-11065228-B2 | Antifungal agents | DPM1, AADAC, PIK3C3 | CYP19A1 2141/4885CNR2 1354/4885MAPT 3096/4885 |
| US-20190314333-A1 | ANTIFUNGAL AGENTS | DPM1, AADAC, PIK3C3 | CYP19A1 2141/4885CNR2 1354/4885MAPT 3096/4885 |
| US-10596150-B2 | Antifungal agents | DPM1, AADAC, PIK3C3 | CYP19A1 2141/4885CNR2 1354/4885MAPT 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.